Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients with Myelofibrosis.

submitted by: mcgheekkm

Dr. Animesh Pardanani, Assistant Professor of Medicine and Consultant in the Division of Hematology at Mayo Clinic in Rochester, MN, Discusses his article, coauthored with Dr. Ayalew Tefferi, on potential complications from withdrawal of ruxolitinib. Available at: http://www.mayoclinicproceedings.com/content/early/recent.

New Drug Provides Rapid, Lasting Relief for Myelofibrosis Patients

submitted by: mdanderson

There are no approved drugs for this punishing and lethal bone marrow disease. Patients on an MD Anderson-led study gained weight and relief from pain and other symptoms.